MAR 23, 2021 9:00 AM PDT

Targeted degradation of the enhancer lysine acetyltransferases CBP and p300

Sponsored by: ACD - A Bio-Techne Brand
  • Christopher J. Ott, PhD

    Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
  • Tim Geiger, PhD

    Field Applications Manager - Bio-Techne

Event Date & Time
Date:  March 23, 2021
Time: 9:00am (PST),  12:00pm (EST)
The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
Webinars will be available for unlimited on-demand viewing after live event.

You May Also Like
Loading Comments...